Managing Hyperphosphatemia in Chronic Kidney Disease

Introduction to Phosphate Management

The American Journal of Kidney Diseases recommends starting with dietary phosphorus restriction to 800-1,000 mg/day, and if this fails to control phosphate levels, add phosphate binders—using calcium-based binders initially in CKD stages 3-4, but considering non-calcium binders as first-line in dialysis patients, especially those with vascular calcification or hypercalcemia 1, 2

The National Kidney Foundation suggests maintaining phosphorus between 2.7-4.6 mg/dL in CKD Stages 3-4 1, 2
The National Kidney Foundation recommends maintaining phosphorus between 3.5-5.5 mg/dL in CKD Stage 5 (dialysis patients) 1, 2

The American Journal of Kidney Diseases advises restricting dietary phosphorus to 800-1,000 mg/day when phosphorus exceeds 4.6 mg/dL in CKD stages 3-4, or exceeds 5.5 mg/dL in stage 5 disease 1, 3
The American Journal of Kidney Diseases recommends avoiding phosphate additives in processed foods, which can double phosphorus intake compared to unprocessed foods 4, 5
The American Journal of Kidney Diseases suggests choosing protein sources wisely, as phosphorus content per gram of protein ranges from 12-16 mg; select proteins with lower phosphorus-to-protein ratios 6
The American Journal of Kidney Diseases advises maintaining adequate protein intake, achieving <1,000 mg phosphorus while maintaining adequate protein (1-1.2 g/kg/day) is extremely difficult—expect phosphorus intake of 778-1,444 mg at this protein level 6

The American Journal of Kidney Diseases recommends adding phosphate binders when phosphorus or PTH levels cannot be controlled despite dietary restriction 1, 6
The American Journal of Kidney Diseases suggests starting with calcium-based phosphate binders (calcium acetate or calcium carbonate) as initial therapy in CKD stages 3-4 1, 2
The American Journal of Kidney Diseases advises limiting elemental calcium from binders to ≤1,500 mg/day, with total calcium intake (including dietary) ≤2,000 mg/day 1, 6
The American Journal of Kidney Diseases recommends using non-calcium binders preferentially in patients with severe vascular or soft-tissue calcifications, hypercalcemia, or suppressed PTH (<150 pg/mL on 2 consecutive measurements) 1, 6

The American Journal of Kidney Diseases suggests considering aluminum-based binders for short-term use only (4 weeks maximum, one course only), then switching to other binders for phosphorus >7.0 mg/dL 1, 6
The American Journal of Kidney Diseases recommends considering more frequent dialysis in this setting 1, 6

The American Journal of Kidney Diseases advises maintaining Ca × P product <55 mg²/dL² and target serum calcium in normal range, preferably toward lower end (8.4-9.5 mg/dL) in dialysis patients 1, 2
The American Journal of Kidney Diseases recommends reducing or discontinuing calcium-based binders and switching to non-calcium binders if corrected calcium exceeds 10.2 mg/dL 1, 2